GE HealthCare Technologies Inc. GEHC
At closeNov 13, 2026, 5:32 AM EST
Pre-market · Nov 13, 5:32 AM ET
- YTD
- -0.22%
- 1 year
- +9.15%
- Market cap
- 37.00B
- Revenue (ttm)
- 21.64B
- Profit margin
- 9.95%
- EPS (ttm)
- 4.73
- Shares out
- 452.14M
- P/E ratio
- 17.30
- Forward P/E
- 14.87
- Dividend
- 0.16 (0.19%)
- Ex-dividend date
- Oct 22, 2026
- YTD return
- -0.22%
- 1-year return
- +9.15%
- Volume
- 2.67M
- Avg volume
- 3.63M
- Open
- 82.79
- Previous close
- 82.60
- Day's range
- 81.79 – 83.17
- 52-week range
- 58.75 – 89.77
- Beta
- 0.77
- Analysts
- Buy
- Price target
- 87.85 (+7.3%)
- Earnings date
- Feb 3, 2027
5D -0.37 (-0.45%)
Key statistics
- Enterprise value
- 45.18B
- PEG ratio
- 2.21
- Price / sales
- 1.71
- Price / book
- 3.19
- Dividend yield
- 0.19%
- Payout ratio
- 2.96%
- Revenue growth
- 7.20%
- Free cash flow
- 1.83B
- Total cash
- 2.83B
- Total debt
- 10.41B
- Return on equity
- 20.01%
- Short % of float
- 4.58%
- 50-day average
- 70.06
- 200-day average
- 69.90
Analyst view
Consensus: buy
- Target (low)
- 75.00
- Target (mean)
- 87.85
- Target (high)
- 100.00
- Strong buy5
- Buy10
- Hold7
- Sell0
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 1.56.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 1.55 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 1.20 | 1.34 | +0.14 | +11.67% |
| Jul 29, 2026 | Jun 30, 2026 | 1.04 | 1.13 | +0.09 | +8.65% |
| Apr 29, 2026 | Mar 31, 2026 | 1.04 | 0.99 | -0.05 | -4.81% |
| Feb 4, 2026 | Dec 31, 2025 | 1.40 | 1.44 | +0.04 | +2.86% |
| Oct 29, 2025 | Sep 30, 2025 | 1.05 | 1.07 | +0.02 | +1.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Argus Research | main | Buy | Buy |
| Nov 3, 2026 | UBS | main | Neutral | Neutral |
| Oct 29, 2026 | JP Morgan | main | Neutral | Neutral |
| Oct 29, 2026 | Citigroup | main | Neutral | Neutral |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 29, 2026 | Barclays | main | Overweight | Overweight |
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- gehealthcare.com
News
GE HealthCare: 3 Key Takeaways for Long-Term Investors 
Argus Research Maintains Buy on GE HealthCare Techs, Raises Price Target to $110 
GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoAS 
GE HealthCare Technologies (GEHC) is a Top-Ranked Value Stock: Should You Buy? 
GE HealthCare announces intent to establish MAGNUS Neuro Alliance to unlock new possibilities in MRI for neuroscience 
UBS Maintains Neutral on GE HealthCare Techs, Raises Price Target to $80 - Reported Sunday, GE HealthCare Unveils CE-Marked Allia Celeo, Pairing Real-Time Digital Twin With AI Image Chain That Balances Image Quality And Radiation
JP Morgan Maintains Neutral on GE HealthCare Techs, Raises Price Target to $80 
Citigroup Maintains Neutral on GE HealthCare Techs, Raises Price Target to $79 - RBC Capital Maintains Outperform on GE HealthCare Techs, Raises Price Target to $90
Your note
Sign in to keep a note on GEHC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARDUINI PETER J | Chief Executive Officer | Purchase | Apr 29, 2026 | 259,424 |
| BANKES JEANNETTE | Officer | Stock Award(Grant) | Mar 1, 2026 | 43,892 |
| CULP HENRY LAWRENCE JR. | Director | Stock Award(Grant) | May 6, 2026 | 499,917 |
| GROGAN WILLIAM K. | Chief Financial Officer | Stock Award(Grant) | Sep 13, 2026 | 75,096 |
| JIMENEZ FRANK R | General Counsel | Purchase | Apr 29, 2026 | 93,932 |
| KASS-HOUT TAHA | Chief Technology Officer | Stock Award(Grant) | Mar 1, 2026 | 92,909 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Inc. | 8.37% | 37,864,164 | 3.10B | Jun 29, 2026 |
| Blackrock Inc. | 8.29% | 37,467,843 | 3.07B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.57% | 29,724,359 | 2.43B | Jun 29, 2026 |
| State Street Corporation | 4.61% | 20,861,566 | 1.71B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.48% | 20,275,526 | 1.66B | Jun 29, 2026 |
| Invesco Ltd. | 4.05% | 18,296,350 | 1.50B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 5.33% | 24,107,613 | 1.97B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 14,443,072 | 1.18B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.61% | 11,786,376 | 964.60M | Jun 29, 2026 |
| VANGUARD WINDSOR FUNDS-Vanguard Windsor II Fund | 2.40% | 10,850,329 | 887.99M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.18% | 9,856,342 | 806.64M | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 9,431,760 | 771.90M | Sep 29, 2026 |